Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
- Publication
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Medical Anatomy
Oligodendrocyte Ablation As A Tool To Study Demyelinating Diseases, Ahdeah Pajoohesh-Ganji, Robert H. Miller
Oligodendrocyte Ablation As A Tool To Study Demyelinating Diseases, Ahdeah Pajoohesh-Ganji, Robert H. Miller
Anatomy and Regenerative Biology Faculty Publications
Multiple sclerosis (MS) is an autoimmune mediated neurodegenerative disease characterized by demyelination and oligodendrocyte (OL) loss in the central nervous system and accompanied by local inflammation and infiltration of peripheral immune cells. Although many risk factors and symptoms have been identified in MS, the pathology is complicated and the cause remains unknown. It is also unclear whether OL apoptosis precedes the inflammation or whether the local inflammation is the cause of OL death and demyelination. This review briefly discusses several models that have been developed to specifically ablate oligodendrocytes in an effort to separate the effects of demyelination from inflammation.
Il-15 Mediates Mitochondrial Activity Through A Pparšæ-Dependent-Pparš¼-Independent Mechanism In Skeletal Muscle Cells, ShantaĆ© M. Thornton, James E. Krolopp, Marcia J. Abbott
Il-15 Mediates Mitochondrial Activity Through A Pparšæ-Dependent-Pparš¼-Independent Mechanism In Skeletal Muscle Cells, ShantaĆ© M. Thornton, James E. Krolopp, Marcia J. Abbott
Health Sciences and Kinesiology Faculty Articles
Molecular mediators of metabolic processes, to increase energy expenditure, have become a focus for therapies of obesity. The discovery of cytokines secreted from the skeletal muscle (SKM), termed āmyokines,ā has garnered attention due to their positive effects on metabolic processes. Interleukin-15 (IL-15) is a myokine that has numerous positive metabolic effects and is linked to the PPAR family of mitochondrial regulators. Here, we aimed to determine the importance of PPARš¼ and/or PPARšæ as targets of IL-15 signaling. C2C12 SKM cells were differentiated for 6 days and treated every other day with IL-15 (100 ng/mL), a PPARš¼ inhibitor (GW-6471), a PPARšæ ā¦
Looking To The Future Of Stroke Treatment: Combining Recanalization And Neuroprotection In Acute Ischemic Stroke, Michael E. Maniskas
Looking To The Future Of Stroke Treatment: Combining Recanalization And Neuroprotection In Acute Ischemic Stroke, Michael E. Maniskas
Theses and Dissertations--Neuroscience
Stroke is the 5th leading cause of death in the U.S. with 130,000 deaths and around 800,000 affected annually. Currently, there is a significant disconnect between basic stroke research and clinical stroke therapeutic needs. Few animal models of stroke target the large vessels that produce cortical deficits seen in the clinical setting. Also, current routes of drug administration, intraperitoneal and intravenous, do not mimic the clinical route of intra-arterial drug administration. To bridge this divide, we have retro-engineered a mouse model of stroke from the current standard of care for emergent large vessel occlusion (ELVO) stroke, endovascular thrombectomy, to ā¦